NASDAQ$NOTV
Inotiv Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Inotiv's Q3 2022 financial results were announced, showing revenue growth driven by DSA and RMS segments.
Inotiv reported record revenues, Adjusted EBITDA, and backlog in Q3 2022, driven by organic growth, acquisitions, and favorable pricing. The company continued to expand its portfolio of services and progress its capacity expansion initiatives.
- Revenue increased due to a rise in DSA revenue and incremental RMS revenue.
- Gross profit increased due to higher DSA and RMS gross profit.
- Operating expenses increased due to acquisitions and strategic investments.
- Continued investing in internal capabilities to provide additional service offerings such as laboratory solutions, pathology services, biotherapeutics and genetic toxicology.
Headline financials
Revenue & EPS history
Inotiv · Revenue · Quarterly
$173M
Revenue by segment
Inotiv · $182M total across 2 segments · Q3 2022
- RMS$134M—73.7%
- DSA$47.9M—26.3%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+0.4%
Avg return
Earnings day
+3.5%
Avg return
5 days after
+5.6%
Avg return
30 days after
39%
25 / 64 earnings
Positive
+51.3%
Q4 2022
Best reaction
-35.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -3.6% | -0.2% | -72.5% | |
| Q1 2026 | -14.3% | -33.3% | -7.1% | |
| Q4 2025 | -6.3% | -9.6% | -42.6% | |
| Q2 2025 | +11.2% | +4.5% | +33.8% | |
| Q1 2025 | -12.9% | -8.9% | -41.8% | |
| Q4 2024 | +0.8% | -2.6% | +7.4% | |
| Q3 2024 | +5.0% | -5.0% | -15.7% | |
| Q2 2024 | +0.9% | -13.2% | -17.0% | |
| Q1 2024 | +15.0% | +45.5% | +126.5% | |
| Q4 2023 | -24.6% | -7.1% | +17.2% | |
| Q3 2023 | -35.7% | -40.7% | -49.0% | |
| Q2 2023 | -7.0% | +0.2% | -13.1% | |
| Q1 2023 | +4.5% | +4.4% | -30.1% | |
| Q4 2022 | +51.3% | +67.4% | +47.4% | |
| Q3 2022 | +24.9% | +33.9% | +16.1% | |
| Q2 2022 | +42.5% | +60.3% | +21.1% | |
| Q1 2022 | -18.7% | -28.8% | -47.9% | |
| Q4 2021 | -13.0% | +9.7% | -19.8% | |
| Q3 2021 | +6.5% | +3.2% | +13.1% | |
| Q2 2021 | +4.2% | +9.3% | +9.6% | |
| Q1 2021 | +25.2% | +34.7% | +48.4% | |
| Q4 2020 | +20.9% | +13.6% | +74.3% | |
| Q3 2020 | -12.8% | -15.7% | -10.6% | |
| Q2 2020 | +6.2% | +13.2% | +25.4% | |
| Q1 2020 | -12.3% | -13.1% | -20.4% | |
| Q4 2019 | +13.7% | +10.8% | +34.5% | |
| Q3 2019 | -4.8% | +16.2% | +73.8% | |
| Q2 2019 | -2.9% | -4.8% | -4.3% | |
| Q1 2019 | -4.9% | -2.1% | +31.9% | |
| Q4 2018 | -2.3% | -2.3% | +6.8% | |
| Q3 2018 | +0.0% | +6.7% | +7.3% | |
| Q2 2018 | +0.6% | -2.3% | -5.2% | |
| Q1 2018 | -19.6% | -16.4% | -15.3% | |
| Q4 2017 | -3.9% | -5.7% | -22.1% | |
| Q3 2017 | -4.0% | -2.8% | -9.7% | |
| Q2 2017 | +6.3% | +3.2% | +5.7% | |
| Q1 2017 | +23.1% | +20.9% | +64.8% | |
| Q4 2016 | +10.0% | -1.2% | +17.5% | |
| Q3 2016 | -13.6% | -4.3% | -18.6% | |
| Q2 2016 | -6.9% | — | — | |
| Q1 2016 | -14.3% | — | — | |
| Q4 2015 | -3.1% | — | — | |
| Q3 2015 | -8.6% | — | — | |
| Q2 2015 | -1.9% | — | — | |
| Q1 2015 | -5.5% | — | — | |
| Q4 2014 | -7.5% | — | — | |
| Q3 2014 | +15.2% | — | — | |
| Q2 2014 | -2.3% | — | — | |
| Q1 2014 | -9.8% | — | — | |
| Q4 2013 | +9.6% | — | — | |
| Q3 2013 | +25.9% | — | — | |
| Q2 2013 | +9.6% | — | — | |
| Q1 2013 | +3.4% | — | — | |
| Q4 2012 | -5.9% | — | — | |
| Q3 2012 | +4.8% | — | — | |
| Q2 2012 | -7.5% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2011 | -3.8% | — | — | |
| Q2 2011 | -3.8% | — | — | |
| Q4 2010 | -4.3% | — | — | |
| Q3 2011 | -4.3% | — | — | |
| Q3 2010 | -4.3% | — | — | |
| Q2 2010 | -3.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro